Revision as of 00:11, 3 December 2021 editLowercase sigmabot III (talk | contribs)Bots, Template editors2,291,616 editsm Archiving 1 discussion(s) to Talk:Combined oral contraceptive pill/Archive 2) (bot← Previous edit | Revision as of 18:06, 16 January 2022 edit undoPrimeBOT (talk | contribs)Bots2,048,549 editsm Task 24: template substitution following a TFDTag: AWBNext edit → | ||
Line 1: | Line 1: | ||
{{Talk header|archive_age=365|archive_bot=Lowercase sigmabot III}} | {{Talk header|archive_age=365|archive_bot=Lowercase sigmabot III}} | ||
⚫ | {{Vital article|level=4|topic=Life|class=B}} | ||
⚫ | {{On this day|date1=2013-05-09|oldid1=554295259|date2=2016-05-09|oldid2=719382444|date3=2020-05-09|oldid3=955530999}} | ||
{{WikiProject banner shell|1= | |||
⚫ | {{WikiProject Women's Health |class=C |importance=Top}} | ||
⚫ | {{WikiProject Medicine|class=C |importance=high |reproductive=yes}} | ||
⚫ | {{WikiProject Sexuality|class=C |importance=top}} | ||
⚫ | {{WikiProject Pharmacology|class=B |importance=high}} | ||
⚫ | {{WikiProject Women's History|class=C |importance=mid}} | ||
⚫ | }} | ||
⚫ | {{Reliable sources for medical articles}} | ||
{{User:MiszaBot/config | {{User:MiszaBot/config | ||
| algo = old(365d) | | algo = old(365d) | ||
Line 12: | Line 20: | ||
}} | }} | ||
⚫ | {{Vital article|level=4|topic=Life|class=B}} | ||
{{WikiProjectBannerShell|1= | |||
⚫ | {{WikiProject Women's Health |class=C |importance=Top}} | ||
⚫ | {{WikiProject Medicine|class=C |importance=high |reproductive=yes}} | ||
⚫ | {{WikiProject Sexuality|class=C |importance=top}} | ||
⚫ | {{WikiProject Pharmacology|class=B |importance=high}} | ||
⚫ | {{WikiProject Women's History|class=C |importance=mid}} | ||
⚫ | }} | ||
⚫ | {{On this day|date1=2013-05-09|oldid1=554295259|date2=2016-05-09|oldid2=719382444|date3=2020-05-09|oldid3=955530999}} | ||
⚫ | {{Reliable sources for medical articles}} | ||
{{Archive box| | {{Archive box| | ||
]<br /> | ]<br /> | ||
]}} | ]}} | ||
⚫ | |||
{{dashboard.wikiedu.org assignment | course = Misplaced Pages:Wiki_Ed/Northeastern_University/ENGW_30306,_Advanced_Writing_for_the_Health_Sciences_(Spring_2019) | assignments = ] | reviewers = ] | start_date = 2019-01-08 | end_date = 2019-04-16 }} | {{dashboard.wikiedu.org assignment | course = Misplaced Pages:Wiki_Ed/Northeastern_University/ENGW_30306,_Advanced_Writing_for_the_Health_Sciences_(Spring_2019) | assignments = ] | reviewers = ] | start_date = 2019-01-08 | end_date = 2019-04-16 }} | ||
{{dashboard.wikiedu.org assignment | course = Misplaced Pages:Wiki_Ed/UCSF/Foundations_II_(Summer) | assignments = ], ], ], ], ] | start_date = 2019-07-01 | end_date = 2019-08-23 }} | {{dashboard.wikiedu.org assignment | course = Misplaced Pages:Wiki_Ed/UCSF/Foundations_II_(Summer) | assignments = ], ], ], ], ] | start_date = 2019-07-01 | end_date = 2019-08-23 }} | ||
==Wiki Education Foundation-supported course assignment== | |||
⚫ | ] This article is or was the subject of a Wiki Education Foundation-supported course assignment. Further details are available ]. Student editor(s): ]. Peer reviewers: ]. | ||
{{small|Above undated message substituted from ] by ] (]) 18:06, 16 January 2022 (UTC)}} | |||
== Queen's University Medical Student Editing Initiative == | == Queen's University Medical Student Editing Initiative == | ||
Line 44: | Line 45: | ||
{{reflist-talk}} | {{reflist-talk}} | ||
2. '''Contraindications: '''Under Section:Contraindications we propose adding to the fourth sentence of the first paragraph so it reads "All COCP users have a small increase in the risk of venous thromboembolism compared with non-users; this risk is greatest within the first year of COCP use |
2. '''Contraindications: '''Under Section:Contraindications we propose adding to the fourth sentence of the first paragraph so it reads "All COCP users have a small increase in the risk of venous thromboembolism compared with non-users; this risk is greatest within the first year of COCP use.<ref>{{cite journal |last1=Black |first1=A |last2=Guilbert |first2=E |last3=Costescu |first3=D |last4=Dunn |first4=S |last5=Fisher |first5=W |last6=Kives |first6=S |last7=Mirosh |first7=M |last8=Norman |first8=WV |last9=Pymar |first9=H |last10=Reid |first10=R |last11=Roy |first11=G |last12=Varto |first12=H |last13=Waddington |first13=A |last14=Wagner |first14=MS |last15=Whelan |first15=AM |title=No. 329-Canadian Contraception Consensus Part 4 of 4 Chapter 9: Combined Hormonal Contraception. |journal=Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC |date=April 2017 |volume=39 |issue=4 |pages=229-268.e5 |doi=10.1016/j.jogc.2016.10.005 |pmid=28413042}}</ref> Individuals with any pre-existing medical condition that also increases their risk for blood clots have a more significant increase in risk of thrombotic events with COCP use<ref>{{cite journal |last1=Black |first1=A |last2=Guilbert |first2=E |last3=Costescu |first3=D |last4=Dunn |first4=S |last5=Fisher |first5=W |last6=Kives |first6=S |last7=Mirosh |first7=M |last8=Norman |first8=WV |last9=Pymar |first9=H |last10=Reid |first10=R |last11=Roy |first11=G |last12=Varto |first12=H |last13=Waddington |first13=A |last14=Wagner |first14=MS |last15=Whelan |first15=AM |title=No. 329-Canadian Contraception Consensus Part 4 of 4 Chapter 9: Combined Hormonal Contraception. |journal=Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC |date=April 2017 |volume=39 |issue=4 |pages=229-268.e5 |doi=10.1016/j.jogc.2016.10.005 |pmid=28413042}}</ref>."] (]) 23:06, 3 December 2020 (UTC)(]) | ||
Under Section: Contraindications, we propose to add to the contraindication already stated for women who are breastfeeding due to risks of blood clots by elaborating on the concerns about the transient risk of COCPs on breast milk production as well as clarify when COPCs are generally safe to use again by postpartum women breastfeeding or not. The additions would be "While studies have demonstrated conflicting results about the effects of COPCs on lactation duration and milk volume, there exist concerns about the transient risk of COCPs on breast milk production when breastfeeding is being established early postpartum.<ref>{{cite journal |last1=Lopez |first1=Laureen M |last2=Grey |first2=Thomas W |last3=Stuebe |first3=Alison M |last4=Chen |first4=Mario |last5=Truitt |first5=Sarah T |last6=Gallo |first6=Maria F |title=Combined hormonal versus nonhormonal versus progestin-only contraception in lactation |journal=Cochrane Database of Systematic Reviews |date=20 March 2015 |doi=10.1002/14651858.CD003988.pub2 |url=https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003988.pub2/full}}</ref> Due to the stated risks and additional concerns on lactation, women who are breastfeeding are not advised to start COPCs until at least six weeks postpartum, while women who are not breastfeeding and have no other risks factors for blood clots may start COCPs after 21 days postpartum.<ref>{{cite book |title=Medical eligibility criteria for contraceptive use. |publisher=World Health Organization |location=Geneva, Switzerland |isbn=9789241549158 |edition=Fifth}}</ref><ref>{{cite web |title=Classifications for Combined Hormonal Contraceptives {{!}} CDC |url=https://www.cdc.gov/reproductivehealth/contraception/mmwr/mec/appendixd.html |website=www.cdc.gov |publisher=Centers for Disease Control and Prevention |language=en-us |date=9 April 2020}}</ref>" ] (]) 08:39, 4 December 2020 (UTC) | Under Section: Contraindications, we propose to add to the contraindication already stated for women who are breastfeeding due to risks of blood clots by elaborating on the concerns about the transient risk of COCPs on breast milk production as well as clarify when COPCs are generally safe to use again by postpartum women breastfeeding or not. The additions would be "While studies have demonstrated conflicting results about the effects of COPCs on lactation duration and milk volume, there exist concerns about the transient risk of COCPs on breast milk production when breastfeeding is being established early postpartum.<ref>{{cite journal |last1=Lopez |first1=Laureen M |last2=Grey |first2=Thomas W |last3=Stuebe |first3=Alison M |last4=Chen |first4=Mario |last5=Truitt |first5=Sarah T |last6=Gallo |first6=Maria F |title=Combined hormonal versus nonhormonal versus progestin-only contraception in lactation |journal=Cochrane Database of Systematic Reviews |date=20 March 2015 |doi=10.1002/14651858.CD003988.pub2 |url=https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003988.pub2/full}}</ref> Due to the stated risks and additional concerns on lactation, women who are breastfeeding are not advised to start COPCs until at least six weeks postpartum, while women who are not breastfeeding and have no other risks factors for blood clots may start COCPs after 21 days postpartum.<ref>{{cite book |title=Medical eligibility criteria for contraceptive use. |publisher=World Health Organization |location=Geneva, Switzerland |isbn=9789241549158 |edition=Fifth}}</ref><ref>{{cite web |title=Classifications for Combined Hormonal Contraceptives {{!}} CDC |url=https://www.cdc.gov/reproductivehealth/contraception/mmwr/mec/appendixd.html |website=www.cdc.gov |publisher=Centers for Disease Control and Prevention |language=en-us |date=9 April 2020}}</ref>" ] (]) 08:39, 4 December 2020 (UTC) |
Revision as of 18:06, 16 January 2022
This is the talk page for discussing improvements to the Combined oral contraceptive pill article. This is not a forum for general discussion of the article's subject. |
|
Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL |
Archives: 1, 2Auto-archiving period: 12 months |
A fact from this article was featured on Misplaced Pages's Main Page in the On this day section on May 9, 2013, May 9, 2016, and May 9, 2020. |
This article has not yet been rated on Misplaced Pages's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Please add the quality rating to the {{WikiProject banner shell}} template instead of this project banner. See WP:PIQA for details.
{{WikiProject banner shell}} template instead of this project banner. See WP:PIQA for details.
{{WikiProject banner shell}} template instead of this project banner. See WP:PIQA for details.
{{WikiProject banner shell}} template instead of this project banner. See WP:PIQA for details.
{{WikiProject banner shell}} template instead of this project banner. See WP:PIQA for details.
|
Ideal sources for Misplaced Pages's health content are defined in the guideline Misplaced Pages:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Combined oral contraceptive pill.
|
Archives |
This page has archives. Sections older than 365 days may be automatically archived by Lowercase sigmabot III when more than 1 section is present. |
This article was the subject of a Wiki Education Foundation-supported course assignment, between 8 January 2019 and 16 April 2019. Further details are available on the course page. Student editor(s): Raachelc (article contribs). Peer reviewers: Raachelc. This article was the subject of a Wiki Education Foundation-supported course assignment, between 1 July 2019 and 23 August 2019. Further details are available on the course page. Student editor(s): Davdang, Cindytrac, Gabidriller, RwengUCSF, AMONGxicillin (article contribs).
Wiki Education Foundation-supported course assignment
This article is or was the subject of a Wiki Education Foundation-supported course assignment. Further details are available on the course page. Student editor(s): DOtter. Peer reviewers: Wendi.gu.
Above undated message substituted from Template:Dashboard.wikiedu.org assignment by PrimeBOT (talk) 18:06, 16 January 2022 (UTC)
Queen's University Medical Student Editing Initiative
Hello,
We are a group of medical students from Queen's University. We are working to improve this article over the next month and will be posting our planned changes on this talk page. We looking forward to working with the existing Misplaced Pages medical editing community to improve this article and share evidence. We welcome feedback and suggestions as we learn to edit. Thank you, Karabesa (talk) 20:19, 23 November 2020 (UTC)
1. Side effects: We propose on inserting the following content under Section:Side Effects and Subsection:Common, “Additionally, taking the pill can be helpful in preventing pelvic inflammatory disease ",and removing "pelvic inflammatory disease" from the statement "On the other hand, the pills can sometimes improve conditions such as pelvic inflammatory disease, dysmenorrhea......". Chickensaladsandwich (talk) 20:53, 2 December 2020 (UTC)Chickensaladsandwich
Under Section:Side Effects and Subsection:Common, we propose changing the final sentence of the second paragraph to include a reduced risk of endometrial cancer as well as ovarian cancer. The sentence would be "Use of oral contraceptives also reduces lifetime risk of ovarian and endometrial cancer." --Sarahliuu (talk) 16:25, 3 December 2020 (UTC)Sarahliuu
Under Section:Side Effects and Subsection:Heart and blood vessels, we propose changing the first sentence of the second paragraph to reflect an update to the Cochrane review that was cited for this claim. The sentence would be "While lower doses of estrogen in COC pills may have a lower risk of stroke and myocardial infarction compared to higher dose estrogen, users of low estrogen dose COC pills still have an increased risk compared to non-users." Karabesa (talk) 02:11, 4 December 2020 (UTC)
References
- Schindler, AE (2013). "Non-contraceptive benefits of oral hormonal contraceptives". International journal of endocrinology and metabolism. 11 (1): 41–7. doi:10.5812/ijem.4158. PMID 23853619.
- Pragout, D; Laurence, V; Baffet, H; Raccah-Tebeka, B; Rousset-Jablonski, C (December 2018). "". Gynecologie, obstetrique, fertilite & senologie. 46 (12): 834–844. doi:10.1016/j.gofs.2018.10.010. PMID 30385358.
- Roach, RE; Helmerhorst, FM; Lijfering, WM; Stijnen, T; Algra, A; Dekkers, OM (27 August 2015). "Combined oral contraceptives: the risk of myocardial infarction and ischemic stroke". The Cochrane database of systematic reviews (8): CD011054. doi:10.1002/14651858.CD011054.pub2. PMID 26310586.
2. Contraindications: Under Section:Contraindications we propose adding to the fourth sentence of the first paragraph so it reads "All COCP users have a small increase in the risk of venous thromboembolism compared with non-users; this risk is greatest within the first year of COCP use. Individuals with any pre-existing medical condition that also increases their risk for blood clots have a more significant increase in risk of thrombotic events with COCP use."13svdo (talk) 23:06, 3 December 2020 (UTC)(talk)
Under Section: Contraindications, we propose to add to the contraindication already stated for women who are breastfeeding due to risks of blood clots by elaborating on the concerns about the transient risk of COCPs on breast milk production as well as clarify when COPCs are generally safe to use again by postpartum women breastfeeding or not. The additions would be "While studies have demonstrated conflicting results about the effects of COPCs on lactation duration and milk volume, there exist concerns about the transient risk of COCPs on breast milk production when breastfeeding is being established early postpartum. Due to the stated risks and additional concerns on lactation, women who are breastfeeding are not advised to start COPCs until at least six weeks postpartum, while women who are not breastfeeding and have no other risks factors for blood clots may start COCPs after 21 days postpartum." Smaho22 (talk) 08:39, 4 December 2020 (UTC)
References
- Black, A; Guilbert, E; Costescu, D; Dunn, S; Fisher, W; Kives, S; Mirosh, M; Norman, WV; Pymar, H; Reid, R; Roy, G; Varto, H; Waddington, A; Wagner, MS; Whelan, AM (April 2017). "No. 329-Canadian Contraception Consensus Part 4 of 4 Chapter 9: Combined Hormonal Contraception". Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC. 39 (4): 229-268.e5. doi:10.1016/j.jogc.2016.10.005. PMID 28413042.
- Black, A; Guilbert, E; Costescu, D; Dunn, S; Fisher, W; Kives, S; Mirosh, M; Norman, WV; Pymar, H; Reid, R; Roy, G; Varto, H; Waddington, A; Wagner, MS; Whelan, AM (April 2017). "No. 329-Canadian Contraception Consensus Part 4 of 4 Chapter 9: Combined Hormonal Contraception". Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC. 39 (4): 229-268.e5. doi:10.1016/j.jogc.2016.10.005. PMID 28413042.
- Lopez, Laureen M; Grey, Thomas W; Stuebe, Alison M; Chen, Mario; Truitt, Sarah T; Gallo, Maria F (20 March 2015). "Combined hormonal versus nonhormonal versus progestin-only contraception in lactation". Cochrane Database of Systematic Reviews. doi:10.1002/14651858.CD003988.pub2.
- Medical eligibility criteria for contraceptive use (Fifth ed.). Geneva, Switzerland: World Health Organization. ISBN 9789241549158.
- "Classifications for Combined Hormonal Contraceptives | CDC". www.cdc.gov. Centers for Disease Control and Prevention. 9 April 2020.
3. Role of placebo pills: Under Section: Role of placebo pills, we propose to add two sentences briefly detailing the supplementation of COCPs with folic acid. The following sentences will be added to the end of the paragraph: “As well, birth control pills, such as COCPs, are often fortified with folic acid as it is recommended to take folic acid supplementation months prior to pregnancy to decrease the likelihood of neural tube defects in infants. With folic acid fortification, people who have been taking COCPs for months before pregnancy may already have sufficient amounts.” sbk1998 (talk) 19:10, 4 December 2020 (UTC)
References
- Viswanathan, Meera; Treiman, Katherine; Kish Doto, Julia; Middleton, Jennifer C; Coker-Schwimmer, Emmanuel JL; Nicholson, Wanda K (Jan 2017). "Folic Acid Supplementation: An Evidence Review for the U.S. Preventive Services Task Force". U.S. Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews.: 4-05214-EF-1. PMID 28151610.
- Lassi, Zohra; Bhutta, Zulfiqar (April 2012). "Clinical utility of folate-containing oral contraceptives". International Journal of Women's Health (4): 185-190. doi:10.2147/IJWH.S18611. PMID 22570577.
{{cite journal}}
: CS1 maint: unflagged free DOI (link) - Viswanathan, Meera; Treiman, Katherine; Kish Doto, Julia; Middleton, Jennifer C; Coker-Schwimmer, Emmanuel JL; Nicholson, Wanda K (Jan 2017). "Folic Acid Supplementation: An Evidence Review for the U.S. Preventive Services Task Force". U.S. Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews.: 4-05214-EF-1. PMID 28151610.
- Lassi, Zohra; Bhutta, Zulfiqar (April 2012). "Clinical utility of folate-containing oral contraceptives". International Journal of Women's Health (4): 185-190. doi:10.2147/IJWH.S18611. PMID 22570577.
{{cite journal}}
: CS1 maint: unflagged free DOI (link)
- Thanks for sharing these improvements. Note @Smaho22 and Sbk1998: Multiple use of the same reference- tech tip. When you add your references while editing, you can see the options "automatic... Manual... Re-use". The first time you add the citation (if it is not already used in an article, click "automatic" and add your PMID, DOI, or website, then click "generate" to fill the template. The second time you want to use the same citation in an article, click "reusue" and search for your citation in the list. This adds in the a,b,c versus duplicating the citation in the list. If possible, practice this in your sandbox before editing live on Monday.JenOttawa (talk) 16:57, 7 December 2020 (UTC)
- Selected anniversaries (May 2013)
- Selected anniversaries (May 2016)
- Selected anniversaries (May 2020)
- All unassessed articles
- C-Class women's health articles
- Top-importance women's health articles
- WikiProject Women's Health articles
- C-Class medicine articles
- High-importance medicine articles
- C-Class reproductive medicine articles
- High-importance reproductive medicine articles
- Reproductive medicine task force articles
- All WikiProject Medicine pages
- C-Class Sexology and sexuality articles
- Top-importance Sexology and sexuality articles
- WikiProject Sexology and sexuality articles
- B-Class pharmacology articles
- High-importance pharmacology articles
- WikiProject Pharmacology articles
- C-Class Women's History articles
- Mid-importance Women's History articles
- All WikiProject Women-related pages
- WikiProject Women's History articles